IL166552A0 - Pyrimidine derivatives and their use as cb2 modulators - Google Patents

Pyrimidine derivatives and their use as cb2 modulators

Info

Publication number
IL166552A0
IL166552A0 IL16655205A IL16655205A IL166552A0 IL 166552 A0 IL166552 A0 IL 166552A0 IL 16655205 A IL16655205 A IL 16655205A IL 16655205 A IL16655205 A IL 16655205A IL 166552 A0 IL166552 A0 IL 166552A0
Authority
IL
Israel
Prior art keywords
modulators
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
IL16655205A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31948030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL166552(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0219501A external-priority patent/GB0219501D0/en
Priority claimed from GB0309326A external-priority patent/GB0309326D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL166552A0 publication Critical patent/IL166552A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16655205A 2002-08-21 2005-01-27 Pyrimidine derivatives and their use as cb2 modulators IL166552A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0219501A GB0219501D0 (en) 2002-08-21 2002-08-21 Compounds
GB0309326A GB0309326D0 (en) 2003-04-24 2003-04-24 Compounds
PCT/EP2003/009217 WO2004018433A1 (en) 2002-08-21 2003-08-19 Pyrimidine derivatives and their use as cb2 modulators

Publications (1)

Publication Number Publication Date
IL166552A0 true IL166552A0 (en) 2006-01-15

Family

ID=31948030

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16655205A IL166552A0 (en) 2002-08-21 2005-01-27 Pyrimidine derivatives and their use as cb2 modulators
IL185549A IL185549A0 (en) 2002-08-21 2007-08-27 Pyrimidine derivatives and their use as cb2 modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL185549A IL185549A0 (en) 2002-08-21 2007-08-27 Pyrimidine derivatives and their use as cb2 modulators

Country Status (34)

Country Link
US (2) US7635701B2 (de)
EP (2) EP1539712B1 (de)
JP (1) JP4583174B2 (de)
KR (1) KR20050058367A (de)
CN (1) CN100351239C (de)
AP (1) AP2005003219A0 (de)
AR (1) AR041016A1 (de)
AT (2) ATE489369T1 (de)
AU (1) AU2003264076B2 (de)
BR (1) BR0313676A (de)
CA (1) CA2495880C (de)
CY (1) CY1107871T1 (de)
DE (2) DE60335151D1 (de)
DK (1) DK1539712T3 (de)
EA (2) EA010130B1 (de)
EC (1) ECSP055613A (de)
ES (1) ES2295682T3 (de)
IL (2) IL166552A0 (de)
IS (1) IS7749A (de)
MA (1) MA27428A1 (de)
MX (1) MXPA05001960A (de)
MY (1) MY137053A (de)
NO (1) NO20051451L (de)
NZ (1) NZ537886A (de)
OA (1) OA12910A (de)
PE (1) PE20040898A1 (de)
PL (1) PL376047A1 (de)
PT (1) PT1539712E (de)
SI (1) SI1539712T1 (de)
TW (1) TW200410946A (de)
UA (1) UA83194C2 (de)
UY (1) UY27939A1 (de)
WO (1) WO2004018433A1 (de)
ZA (1) ZA200500913B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
EP1546115A4 (de) 2002-09-27 2010-08-04 Merck Sharp & Dohme Substituierte pyrimidine
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
EP2543376A1 (de) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazin Kinasehemmer
MX2007002208A (es) 2004-08-25 2007-05-08 Targegen Inc Compuestos hetrociclicos y metodos de uso.
GB0517188D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
RU2589878C2 (ru) 2005-11-01 2016-07-10 Таргеджен, Инк. Би-арил-мета-пиримидиновые ингибиторы киназ
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007070760A2 (en) * 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US20090275611A1 (en) * 2006-04-07 2009-11-05 Boehringer Ingelheim International Gmbh Compounds Which Modulate The CB2 Receptor
EP2081905B1 (de) 2006-07-28 2012-09-12 Boehringer Ingelheim International GmbH Sulfonyl verbindungen als cb2 rezeptor modulatoren
JP5159630B2 (ja) * 2006-09-13 2013-03-06 協和発酵キリン株式会社 縮環複素環誘導体
MX2009002888A (es) 2006-09-25 2009-03-31 Boehringer Ingelheim Int Compuestos que modulan el receptor cb2.
CA2664621A1 (en) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives
WO2008048914A1 (en) * 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
CA2695613A1 (en) 2006-12-19 2008-06-26 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
CN101918832A (zh) * 2007-11-06 2010-12-15 爱默蕾大学 鉴定安全的nmda受体拮抗剂的方法
US8546563B2 (en) 2007-11-07 2013-10-01 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2326629B1 (de) 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Den cb2-rezeptor modulierende sulfonverbindungen
AP2011005674A0 (en) 2008-09-25 2011-04-30 Boehringer Ingelheim Int Sulfonyl compounds which selectively modulate the CB2 receptor.
TW201031650A (en) * 2008-12-02 2010-09-01 Organon Nv 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
BRPI1013493A2 (pt) * 2009-03-30 2016-04-05 Astellas Pharma Inc composto de pirimidina
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
WO2011037795A1 (en) 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
CA2806821C (en) * 2010-07-29 2017-05-09 Astellas Pharma Inc. Fused ring pyridine compound
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2014143661A1 (en) * 2013-03-15 2014-09-18 Waterfi, Llc Method for water-proofing elecronic components
EP2803668A1 (de) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole
JP6534997B2 (ja) * 2013-10-23 2019-06-26 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 神経変性疾患及び疼痛の予防及び治療における使用のための化合物
BR112018071518A2 (pt) 2016-04-22 2019-02-19 Receptor Life Sciences, Inc. compostos medicinais à base de planta de ação rápida e suplementos nutricionais
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
AU2019385420A1 (en) 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518A (en) 1848-04-18 Geaijst-drieb
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
HUT63941A (en) * 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
AU677783B2 (en) 1992-06-10 1997-05-08 Elan Pharma International Limited Surface modified nsaid nanoparticles
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
PL185544B1 (pl) 1995-02-13 2003-05-30 Nowa pochodna podstawionego izoksazolu i środek farmaceutyczny
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
EP0850228A1 (de) * 1995-09-01 1998-07-01 Signal Pharmaceuticals, Inc. Pyrimidin carbonsaüre-amide und ähnliche verbindungen und verfahrens zu behandlung von entzündungszustanden
US5811428A (en) 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
KR100508910B1 (ko) 1995-10-17 2006-04-20 알티피 파마 코포레이션 불용성약물방출
FR2742148B1 (fr) 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
DK1288206T3 (da) 1996-04-12 2008-11-24 Searle Llc Substituerede benzensulfonamidderivater som prolægemidler af COX-2-inhibitorer
EE03680B1 (et) 1996-07-18 2002-04-15 Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE317845T1 (de) 1997-09-05 2006-03-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
ATE233549T1 (de) 1998-06-19 2003-03-15 Skyepharma Canada Inc Neues verfahren zur herstellung von partikeln wasserunlöslicher komponenten im grössenbereich bis 2000 nm
EP1117384A1 (de) 1998-10-01 2001-07-25 Elan Pharma International Limited Nanopartikelformulierungen mit kontrollierter wirkstofffreisetzung
WO2000026216A1 (en) 1998-11-03 2000-05-11 Glaxo Group Limited Pyrazolopyridine derivatives as selective cox-2 inhibitors
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
EP1133280A1 (de) 1998-11-20 2001-09-19 RTP Pharma Inc. Verfahren zur herstellung stabiler suspensionen von unlöslichen mikropartikeln
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
JP2002538157A (ja) 1999-02-27 2002-11-12 グラクソ グループ リミテッド ピラゾロピリジン
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
WO2001041760A2 (en) 1999-12-08 2001-06-14 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
HU230396B1 (hu) 2000-06-28 2016-04-28 Smithkline Beecham Plc Nedves őrlési eljárás
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
JP4141830B2 (ja) 2000-08-31 2008-08-27 エフ．ホフマン−ラ ロシュ アーゲー 細胞増殖の阻害剤としての７−オキソ−ピリドピリミジン類
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
EP1363632B1 (de) 2001-01-29 2010-08-25 The University of Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
JP2005508833A (ja) 2001-02-20 2005-04-07 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャネル・モジュレーターとしての２，４−ジ置換ピリミジン−５−カルボキサミド誘導体
FR2839718B1 (fr) 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
EP1539693B9 (de) 2002-06-19 2008-10-08 Schering Corporation Agonisten des cannabinoidrezeptors
MXPA04012855A (es) 2002-06-28 2005-04-19 Yamanouchi Pharma Co Ltd Derivado de diaminopirimidincarboxiamida.
ES2273077T3 (es) 2002-08-21 2007-05-01 Glaxo Group Limited Derivados de 2-fenilamino-4-trifluorometil-5 (bencil- o piridin-4-il-metil) carbamoilpirimidina como moduladores selectivos del receptor cannabinoide cb2.
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
EP1546115A4 (de) 2002-09-27 2010-08-04 Merck Sharp & Dohme Substituierte pyrimidine
GB0222495D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands

Also Published As

Publication number Publication date
KR20050058367A (ko) 2005-06-16
CY1107871T1 (el) 2013-06-19
DE60317348T2 (de) 2008-08-28
EP1878725A2 (de) 2008-01-16
OA12910A (en) 2006-10-13
ECSP055613A (es) 2005-04-18
EA200700934A1 (ru) 2007-08-31
SI1539712T1 (sl) 2008-04-30
MXPA05001960A (es) 2005-04-28
EA012703B1 (ru) 2009-12-30
IS7749A (is) 2005-03-17
DE60335151D1 (de) 2011-01-05
NO20051451D0 (no) 2005-03-18
ZA200500913B (en) 2006-07-26
AU2003264076B2 (en) 2007-09-20
WO2004018433A1 (en) 2004-03-04
HK1079193A1 (en) 2006-03-31
NO20051451L (no) 2005-03-18
JP2006501228A (ja) 2006-01-12
EP1539712B1 (de) 2007-11-07
US7635701B2 (en) 2009-12-22
TW200410946A (en) 2004-07-01
PE20040898A1 (es) 2005-01-07
CA2495880C (en) 2010-04-27
NZ537886A (en) 2007-05-31
ES2295682T3 (es) 2008-04-16
EA010130B1 (ru) 2008-06-30
DK1539712T3 (da) 2008-03-17
US20100041654A1 (en) 2010-02-18
AP2005003219A0 (en) 2005-03-31
CN100351239C (zh) 2007-11-28
BR0313676A (pt) 2005-06-21
EP1878725A3 (de) 2008-01-30
DE60317348D1 (de) 2007-12-20
AU2003264076A1 (en) 2004-03-11
IL185549A0 (en) 2008-01-06
CA2495880A1 (en) 2004-03-04
PT1539712E (pt) 2008-02-08
MA27428A1 (fr) 2005-07-01
CN1688552A (zh) 2005-10-26
EP1878725B1 (de) 2010-11-24
UA83194C2 (ru) 2008-06-25
MY137053A (en) 2008-12-31
EP1539712A1 (de) 2005-06-15
ATE489369T1 (de) 2010-12-15
PL376047A1 (en) 2005-12-12
US20060293354A1 (en) 2006-12-28
UY27939A1 (es) 2004-03-31
JP4583174B2 (ja) 2010-11-17
ATE377591T1 (de) 2007-11-15
AR041016A1 (es) 2005-04-27
EA200500392A1 (ru) 2005-08-25

Similar Documents

Publication Publication Date Title
IL185549A0 (en) Pyrimidine derivatives and their use as cb2 modulators
SI1487805T1 (sl) Pirimidinski derivati
AP2004003110A0 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
TWI349671B (en) Novel adenine derivative and its use
PL375390A1 (en) 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
PL375395A1 (en) 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
IL163940A0 (en) Aryl substituted pyrimidines and the use thereof
AU2003249909A1 (en) Phenoxypropenylphenyl derivatives and their use as herbicides
IL182136A0 (en) Novel pyrimidine derivatives and their use as ppar-alpha modulators
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
AU2003202091A8 (en) Guanidine derivatives
AU2003216221A1 (en) Attachment and articles using same
GB0220214D0 (en) Compounds and their use
AU2003206694A1 (en) Substituted alkyl uracils and the use thereof
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003205963A1 (en) Azaphenylalanine derivatives and their use as antithrombotic agents
AU2002368112A1 (en) Pyrimidine derivatives
AU2003215379A1 (en) Substituted pyrimidinones and pyrimidinthiones
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses
AU2003236937A1 (en) School supply - universal
GB0227443D0 (en) Pyrimidine derivatives
EP1499338A4 (de) 7-hydroxy-16alpha-fluor-5-androsten-17-one und 7-hydroxy-16alpha-fluor-5-androstan-17-one und ihre derivate
TW556499U (en) Hammock
GB0219304D0 (en) Pyrimidine derivatives